ANALYSIS OF EXPRESSION OF MIRNA AND MRNA IN THE CELLULAR MATERIAL OF THE STOMACH LINING OBTAINED BY ESOPHAGOGASTRODUODENOSCOPY IN ORDER TO DETECT DYSPLASIA AND STOMACH CANCER

miRNA and mRNA are highly specific molecular markers, with their own unique expression profile for each type of tissue. They can become a valuable tool in clinical practice in addition to routine esophagogastroduodenoscopy.
Purpose. To study the prospects of using a classifier based on miRNA and mRNA profiling in cytological samples for detecting dysplasia and stomach cancer, as well as to compare the obtained data with the results of profiling of 7 miRNAs used for the analysis of both histological and cytological material.
Materials and methods. The study included 221 cytological preparations: 108 samples of adenocarcinoma, 27 samples of dysplasia, 86 samples of normal mucosa. The expression level of miRNA-145-5p, -150-5p, -21,-20a, -31-5p, -34a-5p, -375, -125b, -196b, -106b and mRNA of the following genes: TERT, CDKN2A, CKS2, FN1, was determined using real-time reverse transcription polymerase chain reaction. Quantitative comparison of two independent samples for was performed using the Mann-Whitney test. The samples were stratified into different groups using the C5.0 algorithm.
Results: when examining cytological samples in cases of miRNA-125b, 145, -196b, -21, -375 and TERT, СKS2, FN1 mRNA, there was achieved a high level of significance of differences in the cancer/norm group; miRNA-375 and FN1 mRNA in the cancer/dysplasia group and miRNA-145, -196b, -20a, and СKS2, TERT mRNA in the norm/dysplasia groups. When comparing the results for the 7 miRNAs that were used to analyze both histological and cytological material, several differences was noted.
Conclusion. The practical use of miRNA and mRNA expression (in cytological material data mining technology does not allow differentiating dysplasia and cancer but can help in identifying "high-risk patients" who should repeat esophagogastroduodenoscopy with multifocal forceps biopsy, with mandatory molecular genetic research.

1. Gastric Cancer. Clinical Recommendations. Ministry of Health of the Russian Federation; 2018. 34 p. (in Russian)

2. Yada T., Yokoi C., Uemura N. The current state of diagnosis and treatment for early gastric cancer. Diagnostic and Therapeutic Endoscopy. 2013;2013:241320. https://doi.org/10.1155/2013/241320

3. Avtandilov G.G., Kupryushina N.V. Histoploidometry diagnostics of gastric neoplasms in biopsy samples. Moscow: Izdanie RMAPO; 2008.126 (in Russian).

4. State of cancer care to the population of Russia in 2019 ed. Caprin A.D., Starinsky V.V., Shahzadova А.О. Oncology Research Center. 2020; 239. (In Russian)

5. Kwack W.G., Ho W.J., Ho W.J., Kim J.H., Lee J.H., Kim E.J., Kang H.W., et al. Understanding the Diagnostic Yield of Current Endoscopic Biopsy for Gastric Neoplasm: A Prospective Single-Center Analysis Based on Tumor Characteristics Stratified by Biopsy Number and Site. Medicine (Baltimore). 2016;95(30):4196. https://doi.org/10.1097/MD.0000000000004196

6. Clinical cytology: A practical guide / N.Yu. Polonskaya. – M .: Practical Medicine, 2018; 144

7. Arkhipova A.A., Anischenko V.V. Low-grade dysplasia, endoscopic predictors, management tactics. Surgical practice. 2020;(2):10-14. (in Russian) https://doi.org/10.38181/2223-2427-2020-2-10-14

8. Link A., Schirrmeister W., Langner C., Varbanova M., Bornschein J., Wex T., et al. Differential expression of microRNAs in preneoplastic gastric mucosa. Scientific Reports. 2015; 5: 8270. https://doi.org/10.1038/srep08270

9. Titov S.E., Anishchenko V.V., Poloz T.L., Veryaskina Yu.A., Arkhipova A.A., Ustinov S.N. Differential diagnostics of gastric cancer and precancerous changes of the gastric mucosa using analysis of expression of six microRNAS.] Klinicheskaya Laboratornaya Diagnostika – Russian Clinical Laboratory Diagnostics. 2020; 65 (2): 131-136. (in Russ.). https://doi.org/http://dx.doi.org/10.18821/0869-2084-2020-65-2-131-136

10. Anishchenko V.V., Titov S.E., Poloz T.L., Veryaskina Yu.A., Arkhipova A.A., Bubnov I.V. Dinamic screening of precancerous esophagus using molecular genetic analysis. Siberian journal of oncology. 2020;19(6):38-45 (In Russ.). https://doi.org/10.21294/1814-4861-2020-19-6-38-45

11. Molecular genetic markers of tumors / Edited by N.Ye. Kushlinsky, N.N. Mazurenko, M.V. Nemtsova. Moscow: RAMS Publishing House, 2016; 612]

12. de Jesus B.B., Blasco M.A. Telomerase at the intersection of cancer and aging. Trends in Genetics. 2013;29(9):513-2. https://doi.org/10.1016/j.tig.2013.06.007.

13. Tanaka F, Matsuzaki S, Mimori K, Kita Y, Inoue H, Mori M. Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer. International Journal of Oncology. 2011;39(2):361-72. https://doi.org/10.3892/ijo.2011.1056.

14. Cai X, Liu C, Zhang TN, Zhu YW, Dong X, Xue P. Down‐regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. Journal of Cellular Biochemistry. 2018;6:4717-4728 https://doi.org/10.1002/jcb.26651

15. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., Barbisin M., Xu N.L., Mahuvakar V.R., Andersen M.R., Lao K.Q., Livak K.J., Guegler K.J. Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Research. 2005;33:179 https://doi.org/10.1093/nar/gni178. 16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 2001;25:402-8. 2001;25:402-8. https://doi.org/10.1006/meth.2001.1262.10.1006/meth.2001.1262.

16. Arkhipova A.A., Anischenko V.V. Characteristic of stomach ulcers, complicated by bleeding. Characteristic of stomach ulcers, complicated by bleeding. Acta biomedica scientifica. Acta biomedica scientifica. 2020; 2020; 5(1): 5(1): 42-46(In Russ.) https://doi.org/10.29413/ABS.2020-5.1.5